The company, established in 2016 and later restructured as a private limited entity in 2018, specializes in manufacturing APIs, advanced intermediates, and finished dosage forms. With robust relationships in the pharmaceutical industry, it has built a strong customer base of over 50 clients and achieved an annual turnover exceeding 200 crore. The company operates extensive facilities capable of scaling from lab-scale development to bulk production, supporting its global expansion strategy. Committed to ethical practices and social responsibility, the company aims to make healthcare affordable and accessible worldwide, with export markets across Asia, Latin America, and Africa.

This pharmaceutical company specializes in oncology and has nearly two decades of experience developing generic and specialty drugs. They focus on delivering affordable, world-class chemotherapy medications across a wide range of therapeutic areas. Their robust research and development team possesses expertise in complex drug molecule development, serving diverse markets globally. With over 35 developed generics and specialty drugs, they have filed over 40 dossiers across 25 countries in emerging markets. The company is committed to expanding its presence in the oncology therapeutic area within emerging markets.

Established in 2013, this manufacturer specializes in oncology, focusing on the research, manufacturing, and marketing of high-quality specialty formulations. As a CTD dossier owner and manufacturer, it holds GMP certifications from international regulatory authorities, including USFDA, MHRA, and PIC/S, ensuring compliance with stringent quality standards. The manufacturer operates a state-of-the-art facility in Hyderabad, India, designed to meet global regulatory requirements. As a CTD dossier owner and manufacturer, its products are distributed worldwide. With a commitment to innovation and quality, the manufacturer aims to provide the best options to oncologists and their patients.